Covaxin effectively neutralises Alpha, Delta variants, says US research institute
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India Covaxin efficacy against Alpha, Delta COVID-19 variants PTI
Updated Jun 30, 2021, 8:03 AM IST
India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.
NIH-funded adjuvant improves the efficacy India s COVID-19 vaccine
Jun 30 2021
An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.
Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine s effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19.
Ending a global pandemic requires a global response. I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India.
Covaxin effectively neutralises Delta variant of Covid, says top US health institute newindianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newindianexpress.com Daily Mail and Mail on Sunday newspapers.
Covaxin neutralises both Alpha, Delta variants of Covid effectively, research by top US health institute finds
SECTIONS
Covaxin neutralises both Alpha, Delta variants of Covid effectively, research by top US health institute findsET Online
Last Updated: Jun 30, 2021, 11:01 AM IST
Share
Synopsis
The vaccine has so far been given to around 25 million recipients in India and elsewhere. Interim results from Covaxin s Phase 3 trial have reportedly shown over 78% efficacy against symptomatic disease, 100% efficacy against severe infection and 70% efficacy against asymptomatic infection.
India s Covaxin effectively neutralises Delta and Alpha variants of coronavirus: Top US health institute
Bharat Biotech s Covaxin, India s only domestically developed Covid vaccine, can make antibodies that can neutralise both Alpha and
India's Covaxin effectively neutralises Delta variant of Covid, says U.S.' health research institute thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.